Category: Biolase Technology Inc.
Here's a look at some of the top Wall Street stories for medical device companies this week: Hologic's CEO praises its activist investor; Lantheus spikes IPO plans; Ex-CEO Pignatelli backs down, but not out, in spat with Biolase; Symmetry Medical sells its OEM biz to Tecomet for $450M; Valeant's hostile takeover hopes fade as Allergan war continues
Biolase's scorned former CEO Federico Pignatelli retires from the board of directors, saying that he was effectively forced out by hostilities from other members.
Former Biolase (NSDQ:BIOL) CEO Federico Pignatelli, who was removed from the corner office by a court order earlier this year, also walked away from the company's board of directors.
Scorned Biolase ex-CEO Federico Pignatelli withdraws his lawsuit as the company urges shareholders to welcome new leadership and deny his bid for re-election to the board.
Former Biolase (NSDQ:BIOL) CEO Federico Pignatelli agreed this week to withdraw his lawsuit against the dental devices maker, but he's still pursuing his personal investigation into the company's recent conduct.
Here's a look at some of the top funding stories for medical device companies this week: DICOM Grid raises $6M for cloud-based medical imaging systems; Welch Allyn leads $7M round for Cardiac Insight; Biolase launches $12M private placement amid internal turmoil, shares soar; Trice Medical reels in $12M, ex-Embrella founder O'Donnell
Wall Street rallies as dental laser maker Biolase raises $12 million through a private placement round, even as the company deals with an ongoing civil war involving ousted CEO Federico Pignatelli.
California-based Biolase (NSDQ:BIOL) announced today that it secured $12 million in a private placement funding round, even as the company weathers the internal tumult following the ouster of former CEO Federico Pignatelli.
Ousted Biolase CEO Federico Pignatelli launches an investigation into the device maker, saying he suspects "wrongdoing, mismanagement and corporate governance failures."
Shares of Biolase (NSDQ:BIOL) got a modest boost today, even as a company insider announced a far-reaching investigation into the company's management under the suspicion of wrongdoing.
Biolase CEO Federico Pignatelli is out after a court-ordered shake-up at Biolase.
The boardroom and C-suite at Biolase (NSDQ:BIOL) got a shake-up this week following a Delaware Supreme Court decision in a lawsuit filed by Oracle Partners earlier this year.